Drug Profile

HPV16 RG1 VLP

Alternative Names: HPV16 RG1-VLP; human papilloma virus vaccine; RGVax

Latest Information Update: 20 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PathoVax
Developer National Cancer Institute (USA); PathoVax
Class Papillomavirus vaccines; Virus-like particle vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Human papillomavirus infections

Most Recent Events

27 Feb 2025 Phase-I clinical trials in Human papillomavirus infections (Prevention) in USA (IM) (NCT05985681)
28 Apr 2023 No recent reports of development identified for preclinical development in Human-papillomavirus-infections(Prevention) in USA (Parenteral)
29 Mar 2023 US FDA approves IND application for HPV16 RG1 VLP in Human-papillomavirus-infections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com